November 16, 2015
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Suzanne Hayes
Re: Axsome Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-207393
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the Securities Act), the undersigned, as representative of the several underwriters of the proposed public offering of shares of common stock of Axsome Therapeutics, Inc. (the Company), hereby joins the Companys request that the effective date of the above-referenced Registration Statement, as then amended, be accelerated so that it will be declared effective at 4:00 p.m., Washington D.C. time, on November 18, 2015, or as soon thereafter as is practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that we have effected the distribution of approximately 573 copies of the Companys preliminary prospectus, dated October 30, 2015, through the date hereof, to prospective underwriters, dealers, institutional investors and others.
The undersigned advise that they have complied and will continue to comply with, and that they have been informed by the participating underwriters and dealers that they have complied and will continue to comply with, Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
|
Very truly yours, | |
|
| |
|
LADENBURG THALMANN & CO. INC. | |
|
| |
|
As representative of the several underwriters | |
|
|
|
|
By: |
LADENBURG THALMANN & CO. INC. |
|
|
|
|
|
|
|
By: |
/s/ David Rosenberg |
|
|
Name: David Rosenberg |
|
|
Title: Co-Chief Executive Officer |
[Signature Page to Acceleration Request of the Underwriters]